Boston Scientific
Advancing science for life™

EKOS™ Endovascular System

TREAT THE PATIENT NOT JUST THE CLOT



This is why we EKOS.

A REASON TO INTERVENE IN MORE PE CASES

LOW LYTIC | LOW BLOOD LOSS | LOW TRAUMA

This safe, repeatable and reliable treatment dissolves thrombus quickly with low lytic, low blood loss and low trauma, resulting in proven long-term outcomes. EKOS leverages the power of targeted ultrasonic waves to thin and separate fibrin strands and accelerates lytic dispersion deeper into the clot. The new EKOS+ catheter delivers 50% more ultrasound power to resolve PE clot burden more quickly & completely. Backed by long-term data, EKOS is the first choice, smart choice and right choice.

THE DECISION TO INTERVENE IS BACKED BY PATIENT OUTCOMES AND LONG-TERM CLINICAL EVIDENCE

2014

ULTIMA[1]

Level 1 Prospective RCT n=59 Showed that EKOS was more effective than anticoagulants alone in RV/LV reduction and was just as safe

2015

SEATTLE II[2]

Prospective n=150 Confirmed EKOS improved RV function, pulmonary hypertension and clot burden without an increase in bleeding

2018

OPTALYSE[3]

Prospective n=101 Lower doses and shorter infusion times showed similar efficacy as previous studies Long-term data showed RV re-modeling out to one year

2021

KNOCOUT[4]

Retrospective and Prospective n=1,500 Patient Registry to understand OPTALYSE protocol adoption and to provide additional safety, efficacy, and long-term data to the EKOS data set



90,000 PATIENTS AND COUNTING*

There are 90,000 reasons why physicians choose to intervene in Pulmonary Embolism cases with EKOS. No other device used to treat PE has been studied as much as EKOS. It's a low-risk, minimally-invasive 15-minute procedure. EKOS has been the interventional treatment of choice for patients suffering from PE.

*data on file

EKOS™ Endovascular System

THE FIRST CHOICE

+ Long legacy built on successful patient outcomes and long-term, clinical evidence

THE SMART CHOICE

+ The most studied device in the PE space and the only device with long-term data.[3]
+ Proven to reduce RV/LV ratio by more than 23% on average in as little as 2 hours of therapy[1,2,3]

THE RIGHT CHOICE

+ Low lytic, low blood loss, low trauma



ULTRASONIC CORE TECHNOLOGY

+ Ultrasonic waves accelerate clot dissolution by unwinding and thinning fibrin strands to expose more drug receptor sites; acoustic streaming drives the drug deeper into the clot for safe dissolution

BEFORE EKOS ULTRASOUND



Fibrin protein strands collect in a mesh-like structure strengthening thrombus formation.

AFTER EKOS ULTRASOUND



EKOS Ultrasonic Core Technology unwinds and thins fibrin strands to expose more drug receptor sites.

Introducing EKOS+

SAME PROCEDURE, NOW 50% MORE POWERFUL

ONE 15-MINUTE PROCEDURE

Tailor-made for treating PE, EKOS+ provides interventionalists with more ultrasound power to resolve clot burden more quickly and completely without any required changes to lytic dose, treatment duration, or current clinical practice.

Target Thrombus Safely

Acoustic Pulse Acceleration

Superior Clot Dissolution

CLOT RESOLUTION COMPARISON

With 50% more ultrasound power, EKOS+ delivers 130% more clot lysis than standard CDT and 32% more lysis than conventional EKOS.*



Clot Weight Reduction

*bench data on file



EKOS™ Endovascular System

Product	Working Length	Treatment Zone
500-55106	106 cm	6 cm
500-55112	106 cm	12 cm
500-55118	106 cm	18 cm
500-55124	106 cm	24 cm
500-55130	106 cm	30 cm
500-55140	106 cm	40 cm
500-55150	106 cm	50 cm
500-56112	135 cm	12 cm
500-56130	135 cm	30 cm
500-56140	135 cm	40 cm
500-56150	135 cm	50 cm

5.4 F infusion catheter for all EKOS products

106 cm infusion catheter (0.035" guidewire compatible) with one ultrasonic core matched to corresponding length.

135 cm infusion catheter (0.035" guidewire compatible) with one ultrasonic core matched to corresponding length.

EKOS™+ Endovascular System

Product	Working Length	Treatment Zone
H74939605106080	106 cm	8 cm
H74939605106120	106 cm	12 cm
H74939605106160	106 cm	16 cm
H74939605106200	106 cm	20 cm
H74939605135080	135 cm	8 cm
H74939605135120	135 cm	12 cm
H74939605135160	135 cm	16 cm
H74939605135200	135 cm	20 cm

7.8 F infusion catheter for all EKOS+ products

106 cm infusion catheter (0.035" guidewire compatible) with one ultrasonic core matched to corresponding length.

135 cm infusion catheter (0.035" guidewire compatible) with one ultrasonic core matched to corresponding length.

For more information, please visit www.bostonscientific.com/ekos #whyweEKOS

Sources

[1] Kucher N et al. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circulation. 2014;129:479-486.

[2] Piazza G et al. A Prospective, Single-Arm, Multicenter Trial of Ultrasound-Facilitated, Catheter-Directed, Low-Dose Fibrinolysis for Acute Massive and Submassive Pulmonary Embolism. The SEATTLE II Study. J Amer Coll Cardiol: Cardiovasc Interventions 2015; 8(10):1382-1392.

[3] Tapson V et al. A randomized trial of the optimum duration of acoustic pulse thrombolysis procedure in acute intermediate-risk pulmonary embolism. JACC: Cardiovascular Interventions 2018; 11(14):1401-1410.

[4] An International Pulmonary Embolism Registry Using EKOS (KNOCOUT PE). https://clinicaltrials.gov/ct2/show/NCT03426124

Boston Scientific

Advancing science for life™

Peripheral Interventions
300 Boston Scientific Way
Marlborough, MA 01752-1234
www.bostonscientific.com

For more information contact customer service at 1.888.272.1001.

PI-1322305-AA